Compare StocksPFE vs ZBH

Pfizer Inc. (PFE) vs Zimmer Biomet Holdings, Inc. (ZBH): Which Is the Better Buy in 2026?

As of 2026-06-19, PFE is overvalued at $25, with a DCF intrinsic value of $22 and a margin of safety of -12%. ZBH is undervalued at $88, with an intrinsic value of $116 and a margin of safety of 24%. Of the two, ZBH has the wider margin of safety.

PFE
Pfizer Inc.
$25.21
VS
ZBH
Zimmer Biomet Holdings, Inc.
$87.97

Rewards

PFE
  • Gross margin of 74.8% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • FCF yield of 8.6% is historically attractive — the business generates significant cash relative to its price.
  • Trailing P/E of 19.2x is 37% below the historical average of 30.4x — potentially undervalued relative to its own history.
ZBH
  • Gross margin of 70.2% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • Each dollar of retained earnings has created $3.16 of earning power — management is an exceptional capital allocator.
  • Management has timed buybacks well — 3 out of 4 years showed value-accretive repurchases.

Risks

PFE
  • ROIC has declined by 15.9 percentage points over the past 4 years, which may signal competitive erosion.
  • PEG ratio of 13.77 indicates the stock is expensive relative to its expected growth — the market may be pricing in more growth than analysts project.
  • Free cash flow has declined at a 29.6% CAGR over the past 4 years — a concerning trend.
ZBH

    Key Valuation Metrics

    Learn more →
    PFE
    ZBH
    Valuation
    $12.38B
    Free Cash Flow
    $1.42B
    8.61%
    FCF Yield
    8.34%
    19.24
    Trailing P/E
    22.79
    8.91
    Forward P/E
    9.79
    Quality & Moat
    10.19%
    ROIC
    6.45%
    8.31%
    ROE
    6.07%
    74.80%
    Gross Margin
    70.18%
    13.77
    PEG Ratio
    0.63
    Balance Sheet Safety
    0.57
    Net Debt / Equity
    0.56
    N/A
    Interest Coverage
    N/A
    2.03
    Net Debt / EBITDA
    2.75
    6.61%
    Dividend Yield
    1.07%
    PFE: 8Ties: 3ZBH: 1
    PFEZBH

    Historical Fundamentals

    Learn more →
    PFE

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    ZBH

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    $1 Retained Earnings Test

    Learn more →
    PFE
    N/A
    Net losses over 3 years — test not applicable
    Company had negative cumulative retained earnings
    Σ Retained
    $-10.61B
    Δ Market Cap
    $-146.18B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
    ZBH
    $-4.43
    created per $1 retained over 3 years
    Market Cap Declined
    Σ Retained
    $2.05B
    Δ Market Cap
    $-9.07B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Discounted Cash Flow (DCF) Analysis

    Learn more →
    PFE
    12.3% Overvalued
    Price is 12.3% above estimated fair value
    Current Price: $25.21
    Fair Value: $22.46
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued
    ZBH
    24.3% Margin of Safety
    Price is 24.3% below estimated fair value
    Current Price: $87.97
    Fair Value: $116.16
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued

    Reverse DCF — Market-Implied Growth

    Learn more →
    PFE

    What growth rate is the market pricing in at $25?

    +5.2%
    Market-Implied Owner Earnings Growth
    Standard FCF implies +4.5%

    The market implies +5.2% Owner Earnings growth, above historical trends.

    Standard FCF implies a demanding +4.5%, reflecting heavy growth investment.

    ZBH

    What growth rate is the market pricing in at $88?

    +4.5%
    Market-Implied Owner Earnings Growth
    Standard FCF implies +5.5%

    The market implies +4.5% Owner Earnings growth, below historical trends — potential opportunity.

    Standard FCF implies a more demanding +5.5%, reflecting heavy growth investment expected to generate future returns.

    Economic Moat Score

    Learn more →
    PFE
    35/100
    No Moat
    70+ Wide · 40-69 Narrow · <40 None

    No durable moat detected, though reinvestment efficiency shows some competitive positioning. The business lacks consistent evidence of sustainable advantages.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.
    ZBH
    68/100
    Narrow Moat
    70+ Wide · 40-69 Narrow · <40 None

    Narrow moat with revenue predictability as the key competitive advantage. Improving roic consistency would strengthen the moat.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.

    Forensic Accounting

    Learn more →
    PFE
    -2.53
    Unlikely Manipulator
    Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

    M-Score Trend

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
    ZBH
    -2.58
    Unlikely Manipulator
    Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

    M-Score Trend

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Ownership Breakdown

    Learn more →
    PFE
    Insiders 0.1%Institutions 69.4%Retail & Other 30.5%
    No. of Institutional Holders3,744
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
    ZBH
    Insiders 0.2%Institutions 106.6%
    No. of Institutional Holders1,298
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

    High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

    Insider Buying Activity

    Learn more →
    PFE
    0
    Buys (3M)
    0
    Buys (12M)
    BLAYLOCK RONALD E
    Director
    $499,072
    @ $25.65 · 2025-02-13
    GOTTLIEB SCOTT
    Director
    $28,240
    @ $28.24 · 2024-10-30
    Open market purchases · includes direct & indirect ownership · excludes option exercises
    ZBH
    0
    Buys (3M)
    0
    Buys (12M)
    No open market insider purchases found.
    Open market purchases · includes direct & indirect ownership · excludes option exercises

    Open market purchases · includes direct & indirect ownership · excludes option exercises.

    Insider Selling Activity

    Learn more →
    PFE
    1
    Sells (3M)
    1
    Sells (12M)
    Total value (12M): $51,400
    DAMICO JENNIFER B.
    Officer
    $51,400
    @ $25.70 · 2026-06-09
    DAMICO JENNIFER B.
    Officer
    $64,825
    @ $25.93 · 2025-03-04
    DAMICO JENNIFER B.
    Officer
    $147,714
    @ $28.66 · 2024-08-13
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
    ZBH
    1
    Sells (3M)
    6
    Sells (12M)
    Total value (12M): $1.19M
    YI SANG
    Officer
    $413,216
    @ $82.64 · 2026-05-29
    WINKLER LORI
    Officer
    $250,849
    @ $94.66 · 2026-03-12
    YI SANG
    Officer
    $96,490
    @ $96.49 · 2026-02-12
    YI SANG
    Officer
    $124,302
    @ $103.58 · 2025-09-11
    WINKLER LORI
    Officer
    $156,225
    @ $104.15 · 2025-09-08
    WINKLER LORI
    Officer
    $153,735
    @ $102.49 · 2025-08-18
    YI SANG
    Officer
    $74,011
    @ $92.51 · 2025-06-13
    YI SANG
    Officer
    $95,000
    @ $95.00 · 2025-06-11
    WINKLER LORI
    Officer
    $150,649
    @ $104.40 · 2025-03-05
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

    🎭 Mr. Market's Mood

    Learn more →
    PFE
    FearGreed
    😐Neutral(49/100)

    "Market is pricing this stock without strong emotion in either direction"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
    ZBH
    FearGreed
    😐Neutral(50/100)

    "Market is pricing this stock without strong emotion in either direction"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    ⚖️ Buffett Signal

    Learn more →
    PFE
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Neutral (49)
    ZBH
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Neutral (50)
    View PFE Full AnalysisView ZBH Full Analysis

    Frequently Asked Questions: PFE vs ZBH

    Is Pfizer Inc. or Zimmer Biomet Holdings, Inc. more undervalued in 2026?

    Based on our discounted cash flow model, ZBH trades at a 24.3% margin of safety (intrinsic value $116 vs. price $88), compared to PFE's -12.3% margin of safety (intrinsic $22 vs. $25).

    Which stock has a wider economic moat, Pfizer Inc. or Zimmer Biomet Holdings, Inc.?

    ZBH scores 68/100 (Narrow moat), while PFE scores 35/100 (None moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

    Is Pfizer Inc. in financial distress?

    PFE's Altman Z-Score of 2.1 places it in the Grey zone, signaling elevated bankruptcy risk. ZBH scores 2.4 (Grey zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

    Which company has better free cash flow, Pfizer Inc. or Zimmer Biomet Holdings, Inc.?

    Pfizer Inc. (PFE) generates a 8.6% free cash flow yield, compared to Zimmer Biomet Holdings, Inc.'s 8.3%. A higher FCF yield means the business converts more of its market value into cash that can be returned to shareholders or reinvested.

    Which stock has higher return on invested capital, Pfizer Inc. or Zimmer Biomet Holdings, Inc.?

    PFE earns 10.2% ROIC versus ZBH's 6.5%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.

    Which dividend is safer, Pfizer Inc.'s or Zimmer Biomet Holdings, Inc.'s?

    ZBH's dividend earns a safety score of 85/100 (Very Safe), compared to PFE's 24/100 (Unsafe). ZBH has raised its dividend for 0 consecutive years.

    PFE vs ZBH: Which Is the Better Buy in 2026? | SafetyMargin.io